Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

BELLEVUE, WA, June 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer. PX-12 is a proprietary small molecule inhibitor of thioredoxin, a protein that regulates diverse molecular pathways that contribute to the growth, survival and drug resistance of many cancers.

The primary objective of the Phase 1b dose-escalation trial is to determine the safety and tolerability of a 72-hour continuous infusion of PX-12 given on the first three days of a 21-day cycle. Other objectives of the trial include an evaluation of the pharmacokinetics and pharmacodynamics of the prolonged infusion, together with identification of any anti-tumor activity. The trial is expected to enroll up to 28 patients at three centers in the United States.

About PX-12

PX-12 is a small molecule designed to inhibit thioredoxin-1. Increased levels of thioredoxin-1 have been noted in many types of cancer cells, including hepatoma, lung cancers, squamous cervical carcinoma, primary gastric cancers and colorectal carcinomas. Increased levels of thioredoxin-1 are associated with decreased sensitivity to a variety of common chemotherapy agents and may cause or contribute to drug resistance.

An initial Phase 1 trial of PX-12 in 38 patients with advanced metastatic cancer showed that PX-12 was well tolerated and produced a decrease in plasma concentrations of thioredoxin that was significantly correlated with increased patient survival. Fifteen of the 38 patients achieved stable disease of up to 322 days. Oncothyreon is also currently conducting a Phase 2 trial of PX-12 given as a 3-hour
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2
... - Non-GAAP and GAAP Operating Earnings ... Diluted EPS Up 15%, GAAP Diluted EPS Up 16%, PALO ALTO, ... revenues of $237.4,million, representing an increase of 8.9% over revenues of $217.9 ... growth in sales of products for both life science and industrial,(which includes ...
... Jan. 23 PPD, Inc. (Nasdaq:,PPDI) today announced ... services,into China through an exclusive agreement with Peking ... PPD to begin,immediately providing biopharmaceutical clients with its ... China., "Chinese law makes it extremely difficult ...
... - Increases medical waste disposal capacity and capabilities to facilitate ... growth plans - New state-of-the-art autoclave technology provides environmentally ... operation, - With the addition of the autoclave, one of approximately ten permitted,commercial disposal facilities in the country ... of medical waste ...
Cached Biology Technology:Varian, Inc. Reports First Quarter 2008 Results 2Varian, Inc. Reports First Quarter 2008 Results 3Varian, Inc. Reports First Quarter 2008 Results 4Varian, Inc. Reports First Quarter 2008 Results 5Varian, Inc. Reports First Quarter 2008 Results 6Varian, Inc. Reports First Quarter 2008 Results 7Varian, Inc. Reports First Quarter 2008 Results 8Varian, Inc. Reports First Quarter 2008 Results 9Varian, Inc. Reports First Quarter 2008 Results 10Varian, Inc. Reports First Quarter 2008 Results 11Varian, Inc. Reports First Quarter 2008 Results 12Varian, Inc. Reports First Quarter 2008 Results 13Varian, Inc. Reports First Quarter 2008 Results 14Varian, Inc. Reports First Quarter 2008 Results 15Varian, Inc. Reports First Quarter 2008 Results 16Varian, Inc. Reports First Quarter 2008 Results 17Varian, Inc. Reports First Quarter 2008 Results 18PPD Expands Global Central Lab Services into China 2PPD Expands Global Central Lab Services into China 3Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 2Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 3Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 4
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... affect the connections between nerve cells and influence the ... of the brain that plays a significant role in ... of the study have been published in the journal ... active communication between nerve cells, known as neurons. For ... network where they constantly relay signals to one another. ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... scientists from the University of Leicester has published research which ... babies are being exposed to. Research published today ... Edition of Archives of Disease in Childhood documents ... premature infants as part of their medical care. The ...
... technological centre specialising in marine and food research, ... Third country eXpertise) project. The fundamental aim of ... possible on scientific fishery research programs from the ... to achieve effective coordination and cooperation between countries, ...
... suggests that human male fertility is impacted by long-term ... present in the male reproductive tract, further suggesting a ... genetic test to clarify mechanisms. Now, in a paper ... characterize the phenotype of mice genetically lacking FAAH, fatty ...
Cached Biology News:Research exposes the risk to infants from the chemicals used in liquid medicines 2Research exposes the risk to infants from the chemicals used in liquid medicines 3TXOTX, coordinated international project to contribute to sustainability of the marine resources 2February 2009 highlights from Biology of Reproduction 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... The P5T Series Short Stroke Thrust ... stroke applications where mounting envelopes are limited ... wear bands and internal bumpers provide millions ... applications., Choice of composite bushings or ...
Biology Products: